Shenzhen Innovation Investment Group
Room 2108, Building 4, Zhuoyue Shiji Center, Fuhua 3 road & Jintian Road, Futian Avenue, Shenzhen, Guangdong, 518048, China
Overview
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB, and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Micro Lending
- Venture Capital
Investment portfolio
- Gushengtang Holdings
Participated · Series D · Sep 2017
固生堂中医 operates a nationwide TCM clinic and primary-care chain with more than 30–31 outpatient clinics across 13 important cities and service coverage in 56 cities. The group employs roughly 1,500 TCM experts and reported about 3 million outpatient visits in 2016. Its core offering is standardized, chain‑operated TCM outpatient services combining on‑site clinics, IT systems, centralized herb procurement/quality control, and online consultation to bind patients to family‑doctor style care. Management has launched a “中医合伙人” (doctor‑partner) program that lets doctors take 30% equity in single stores, with guaranteed exit, pledgeable shares, dividend sharing, and suggested 8–10x return potential over eight years. Financially, the company has completed multiple financing rounds from domestic and foreign investors and reported total funding to date of over RMB1.7 billion. 固生堂 emphasizes integration with insurance and hospital networks, and positions itself as a mixed‑ownership, state‑backed chain to support China’s primary‑care and TCM reform goals.
Team
No current team members are available.